Asia is poised to take a leading role in global vaccine research and development
Focal Point |
Vaccine Research in Asia
Looking to the east
Asia is shaping up to be a vaccine powerhouse. The signs are there in funding levels, and combined with Asian governments’ interest in biotechnology, and a highly skilled, highly educated workforce, pharma giants are looking east.
This advertisement feature is produced by Nature Research Custom Media in partnership with the National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN). The advertiser retains responsibility for content. About this content.
Focal Point feature
NIBIOHN scientists are helping researchers pick the right adjuvant for their vaccines.
Two major players in the Japanese pharmaceutical industry are developing the next generation of vaccines.
The BIKEN Group is strengthening its commitment to eradicate serious infectious diseases by developing next-generation vaccines.
Integrating basic and clinical research is key to the development of safe and effective mucosal vaccines taken orally or nasally, says Hiroshi Kiyono of the Institute of Medical Science, the University of Tokyo.
Chiba University's partnership with the University of California San Diego is advancing immunology research and education in a big way.
KM Biologics’ research roots help it successfully innovate in the field of vaccine development.
The International Society for Vaccines is uniting the diverse community of vaccinologists.
From tuberculosis and pneumonia, to Ebola and Zika, a Chinese biotech firm is developing high-quality vaccines to address global health challenges.
Vaccine development at the Institute of Medical Biology, Chinese Academy of Medical Sciences has played a vital role in fighting infectious diseases.